ROP treated with ranibizumab or low-dose bevacizumab may need re-treatment
- Posted on: Apr 27 2023
- Leave a response
This study examined retinopathy of prematurity (ROP) re-treatment rates following initial ROP treatment with anti-VEGF therapy (ranibizumab or bevacizumab) at various doses.
Source: AAO
Posted in: Uncategorized
